Fredun Pharmaceuticals Limited reported its audited standalone financial results for Q4 FY26 and FY26 ended 31st March 2026.

Financial Performance Highlights

Standalone Results (₹ Crore):

Q4 FY26 Performance:

  • Total Income: ₹213.05 Cr (vs. ₹167.41 Cr in Q4 FY25), up 27.27% YoY
  • EBITDA: ₹29.13 Cr (vs. ₹17.44 Cr in Q4 FY25), up 67.05% YoY
  • EBITDA Margin: 13.67% (vs. 10.42% in Q4 FY25), expansion of 326 basis points
  • Net Profit: ₹11.07 Cr (vs. ₹7.07 Cr in Q4 FY25), up 56.47% YoY
  • Net Profit Margin: 5.19% (vs. 4.22% in Q4 FY25), expansion of 97 basis points

FY26 Full Year Performance:

  • Total Income: ₹639.12 Cr (vs. ₹456.27 Cr in FY25), up 40.08% YoY
  • EBITDA: ₹94.79 Cr (vs. ₹55.10 Cr in FY25), up 72.05% YoY
  • EBITDA Margin: 14.83% (vs. 12.08% in FY25), expansion of 276 basis points
  • Net Profit: ₹33.21 Cr (vs. ₹20.81 Cr in FY25), up 59.59% YoY
  • Net Profit Margin: 5.20% (vs. 4.56% in FY25), expansion of 64 basis points

Corporate Actions

The Board of Directors recommended:

  • Dividend of ₹0.70 per share
  • Bonus issue in the ratio of 2:1 (2 fully paid-up equity shares of ₹10 each for every 1 existing share of ₹10 each) to eligible shareholders/warrant holders as on the record date
  • Both proposals are subject to shareholder approval

Operational Highlights and Business Updates

New Product Launches:

  • Launch of premium hormone therapeutics range focused on longevity, hormone health, and performance care
  • Doctor-led, evidence-backed model with digital-first patient engagement
  • Launch of 'DAULCÉL' - premium NAD+ based wellness & longevity platform
  • Expansion into preventive healthcare, healthy aging, and lifestyle wellness segments

Capacity Expansion:

  • Fifth facility expansion at Palghar adding 40,000 sq. ft. manufacturing capacity
  • Expected to be operational by October 2026
  • Will support veterinary, nutraceutical and pharmaceutical formulations
  • Additional 50,000 sq. ft. expansion planned

Credit Rating Update:

  • Infomerics upgraded credit rating to IVR BBB+ (Stable) from IVR BBB (Stable)
  • Rating covers bank facilities of ~₹156.17 crore
  • Strengthened banking confidence and institutional credibility

Management Commentary

Mr. Fredun Medhora, Managing Director, commented that FY26 reflects steady progress in building a diversified and resilient business. Growth is coming across segments with continued strength in generics complemented by increasing traction in nutraceuticals, cosmeceuticals, and pet care. The balanced mix is helping scale more sustainably and reduce dependence on any single segment. The company has started investing in the next phase of growth through new product launches and facility expansion.

Company Business Overview

Fredun Pharmaceuticals Limited is a healthcare and pharmaceuticals company offering a range of products including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. The company is also engaged in manufacturing dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

Forward-Looking Statements Disclaimer

The document contains forward-looking statements that are subject to certain risks and uncertainties including government actions, local, political or economic developments, technological risks, and other factors that could cause actual results to differ materially from those contemplated. The company undertakes no obligation to publicly update these forward-looking statements.